

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0003	<a href="#">E3805</a>	HSD3B1 and Resistance to Androgen Deprivation Therapy Versus Chemohormonal Therapy in E3805	Nima Sharifi/ Cleveland Clinic Foundation
CSC0005	<a href="#">E2197</a>	Proposal for Analysis of a Subset of ER+ Breast Cancer Specimens From ECOG E2197	Hannah Gilmore/ Univ. Hospitals Case Medical Center
CSC0006	<a href="#">E3805</a>	Association of PTEN/ERG Status with Response to ChemoHormonal Therapy Versus Androgen Ablation on E3805	Tamara Lotan/ Johns Hopkins University
CSC0009	<a href="#">NCCTG N0147</a> <a href="#">NSABP C-08</a>	Genotyping of Tumors and Patients with Stage III Colon Cancer: Identifying Genomic Markers Associated with Recurrence and Poor Outcomes (Sample Request of NCCTG N0147, NSABP C-08)	Richard Goldberg/ Ohio State University
CSC0011	<a href="#">S0816</a>	Biomarkers of Early Treatment Response in Advanced Stage Classical Hodgkin Lymphoma Using Specimens From S0816	David Scott/ British Columbia Cancer Agency
CSC0013	<a href="#">S1107</a>	Exome Sequencing of Tumor Tissue Samples Collected from Patients Participating in S1107 "Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ-197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma (pRCC)	Przemyslaw W. Twardowski/ City of Hope National Medical Center
CSC0014	<a href="#">E3805</a>	Assessment of Gene Expression Profiles (GEP) as a Predictor of Benefit From Chemo-Hormonal Therapy in Metastatic Hormone Sensitive	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0017	<a href="#">RTOG 0424</a>	Prognostic and Predictive Markers in High-Risk Low-Grade Gliomas: A Study Based On RTOG0424 (Protocol # NRG-BN-TS006)	Arnab Chakravarti/ Ohio State University
CSC0018	<a href="#">RTOG 9601</a>	Association of PTEN/ERG Status with Response to Salvage Radiation Therapy with or Without Anti-Androgen Therapy: A Study of RTOG 9601	Tamara Lotan/ Johns Hopkins University

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0019	<a href="#">S0800</a>	Immune Gene Expression Profiling of Pre-chemotherapy, Needle Biopsies and Residual Cancer Specimens from the S0800 Neoadjuvant Chemotherapy +/- Bevacizumab Trial	Lajos Pusztai/ Yale Cancer Center
CSC0025	<a href="#">NSABP B-31</a>	Association of Stromal Tumor Infiltrating Lymphocytes (sTIL) with Disease Free Survival in HER2 Positive Breast Cancer Patients Enrolled in NSABP B-31	S. Rim Kim/ NRG Oncology
CSC0027	<a href="#">CALGB-10603</a>	Interaction of NPM1 with FLT3 Mutations in Correlation with Host and Disease Features and Response to Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin or Placebo in the Alliance/CALGB-10603 Study.	Richard Stone/ Dana-Farber Cancer Institute
CSC0028	<a href="#">E3805</a>	Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer from E3805	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0029	<a href="#">NCIC-MA.27</a>	Pharmacogenomics of aromatase inhibitors in patients entered on the MA.27 clinical trial comparing anastrozole and exemestane as adjuvant therapy for early-stage postmenopausal breast cancer.	James Ingle/ Mayo Clinic
CSC0032	<a href="#">E1900</a>	Precision medicine-guided PARP1 inhibitor-induced synthetic lethality in high risk AMLs from E1900 trial.	Tomasz Skorski/ Temple University
CSC0037	<a href="#">RTOG 0521</a>	C-reactive Protein and the Inflammatory State: Novel Prostate Biomarkers of Aggressive Disease Using RTOG 0521 Serum Specimens	William A. Hall/ Medical College of Wisconsin

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0038	<a href="#">S0806</a> <a href="#">S0433</a>	Impact of Mutations in Histone Acetyltransferase Genes CREBBP and EP300 on Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Vorinostat-R-CHOP in S0806, as compared to S0433 (iodine-131 tositumomab plus R-CHOP)	Catharine Smith/ University of Arizona College of Pharmacy
CSC0043	<a href="#">CALGB 89803</a>	Methylated DCR1 as a novel predictive epigenetic biomarker in colon cancer cases from CALGB (Alliance) 89803	William Grady/ Fred Hutchinson Cancer Center
CSC0046	<a href="#">RTOG 0522</a>	A retrospective analysis of RTOG 0522: Does myofibroblast content in the tumor-associated stroma predict response to epidermal growth factor receptor (EGFR) inhibitors in head and neck cancers	Gregory Gan/ University of New Mexico Comprehensive Cancer Center
CSC0048	<a href="#">E3611</a>	Simultaneous Assessment of Biomarkers in the TME and Circulation of Metastatic Melanoma Patients Treated with Ipilimumab and Ipilimumab with Interferon-Alpha in E3611	Ahmad Tarhini/ University of Pittsburgh Cancer Institute
CSC0049	<a href="#">RTOG 96-01</a>	Identifying Early Biomarkers of Anti-Androgen Treatment Resistance from the RTOG 96-01 Clinical Trial	Christopher A. Maher/ Washington University
CSC0050	<a href="#">RTOG 92-02</a> <a href="#">RTOG 94-13</a> <a href="#">RTOG 99-02</a>	Discovery and Validation of Genomic Signature Predictive of Response to Long Term Androgen Deprivation Therapy (ADT) for Prostate Cancer Patients receiving Radiation Therapy as First-Line Treatment in RTOG 92-02, 94-13 and 99-02	Felix Feng/ University of California, San Francisco & Paul Nguyen/ Dana- Farber Cancer Institute/Brigham & Women's Hospital
CSC0053	<a href="#">RTOG 8903</a>	Genomic Analysis of Chemoradiotherapy Response in Muscle-Invasive Bladder Tumors from completed RTOG trials: 8903, 9506, 9706, 9906, 0233, and 0524	Kent Mouw/ Dana- Farber Cancer & Jason Efsthathiou/ Massachusetts General Hospital

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0054	<a href="#">S9800</a> <a href="#">S9911</a> <a href="#">S0016</a>	Assessing the predictive value of minimal residual disease measured by High-throughput sequencing in one year marrow specimens, for progression free survival in Follicular Lymphoma trials S9800, S9911 and S0016	Christopher Carlson/ Fred Hutchinson Cancer Center
CSC0055	<a href="#">E1508</a>	Determinants of clinical outcome in small cell lung cancer using 1st line tumor samples from ECOG 1508: Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib or cixutumumab for patients with extensive stage-small cell lung cancer	Charles Rudin/ Memorial Sloan Kettering Cancer Center
CSC0064	<a href="#">GOG-0218</a>	Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer – Blood-based Angiome Profiling in samples from women enrolled on the Gynecologic Oncology Group (GOG) 0218 trial	Angeles Alvarez Secord/ Duke Cancer Institute
CSC0065	<a href="#">NSABP B-34</a>	Protocol for the Retrospective Analysis of Maf Gene Amplification Determined by Fluorescent in Situ Hybridization in Primary Tumor Samples from the Prospective, Randomized NSABP B-34 Clinical Trial	Alexander H.G. Paterson/ Tom Baker Cancer Center, Calgary
CSC0075	<a href="#">RTOG 9601</a>	Validation of a Genomic Classifier (GC) Model Prognostic of Metastasis and Biochemical Failure in a Cohort of High-Risk Prostate Cancer Patients Treated with Salvage Radiation and Anti-Androgen Therapy (AAT) after Radical Prostatectomy from the RTOG 9601 Clinical Trial	Felix Feng/ University of California, San Francisco & Phuoc T. Tran/ Johns Hopkins University
CSC0076	<a href="#">NSABP B-52</a>	Assessment of critical immune markers including PD-L1, PD-1, CD8, FOXP3 and CD68 and their association with pCR in breast cancer patients enrolled into NSABP/NRG B-52 clinical trial	Katherine Pogue- Geile/ NRG Oncology

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0081	<a href="#">RTOG 9601</a>	The telomere biomarker as a tool to inform decision-making for aggressive salvage therapy in men with rising PSA post prostatectomy in RTOG 9601	Theodore L. DeWeese, MD/ Johns Hopkins University
CSC0082	<a href="#">S0226</a>	Circulating Thymidine Kinase (TK) assay and outcome within SWOG S0226	James Rae/ University of Michigan
CSC0083	<a href="#">RTOG 0126</a>	Validation of a 22-Gene Genomic Classifier to Personalize Radiotherapeutic Dosing in men receiving External Beam Radiotherapy for Localized Intermediate Risk Prostate Cancer in RTOG 01-26	Daniel Spratt/ University of Michigan, Jeff Michalski/ Washington University, Felix Feng/ University of California, San Francisco
CSC0084	<a href="#">E3805</a>	Somatic genomic analyses as predictors of benefit from chemo-hormonal therapy in metastatic hormone sensitive prostate cancer in E3805 CHARTED	Christopher Sweeney/ Dana-Farber Cancer Institute
CSC0085	<a href="#">CALGB 40502</a>	Intrinsic Subtype and Genomic Signatures of Response in CALGB 40502 (ALLIANCE): A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone +/- Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	Daniel Stover/ Ohio State University
CSC0086	<a href="#">CALGB 40502</a>	Tumor Infiltrating Lymphocytes as a Biomarker of Response: CALGB 40502 (ALLIANCE) A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone +/- Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer	Daniel Stover/ Ohio State University

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0089	<a href="#">RTOG 0126</a> <a href="#">RTOG 0415</a> <a href="#">RTOG 0521</a>	Genomic Analysis of Severe, Life-Threatening Urinary and Rectal Toxicities Following Radiotherapy for Prostate Cancer in RTOG 0126, 0415, and 0521	Sarah Kern/ University of Rochester
CSC0091	<a href="#">NSABP B-42</a>	NSABP B-42 clinical validation study of ESR1 mRNA by qRT-PCR as a predictor of benefit from extended adjuvant endocrine therapy with letrozole in postmenopausal women with hormone receptor positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center
CSC0092	<a href="#">NSABP B-42</a>	Prediction of Benefit From Extended Adjuvant Aromatase Inhibitor (AI) Therapy and Risk Stratification for Late Distant Recurrence Using the Breast Cancer Index in Postmenopausal Women with Hormone Receptor-Positive (HR+) Breast Cancer in the NSABP B-42 Trial	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center & Priya Rastogi/ University of Pittsburgh
CSC0093	<a href="#">RTOG 0825</a>	A Molecular Analysis of NRG Oncology/RTOG 0825 to Validate and Refine the Newly Developed NRGGMBM-RPA as Well as Refine the New GBM Nomogram in Primary Glioblastoma Patients Treated with Radiation and Temozolomide	Arnab Chakravarti/ Ohio State University
CSC0095	<a href="#">S0106</a>	Understanding and Predicting Relapse in Acute Myeloid Leukemia Using the S0106 Trial	Jerry Radich/ Fred Hutchinson Cancer Center
CSC0097	<a href="#">NSABP B-42</a>	Genomic Analysis of the NSABP-B42 Extended Adjuvant Endocrine Therapy Trial cohort with the 70-gene MammaPrint Assay	Terry Mamounas/ Orlando Health- University of Florida Health Cancer Center
CSC0102	<a href="#">S0221</a>	Nutrient Insufficiency and paclitaxel-induced peripheral neuropathy in SWOG 0221	Daniel Hertz/ University of Michigan

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0106	<a href="#">NSABP C-08</a> , <a href="#">CALGB 89803</a>	Tumor stromal content as a surrogate for CMS4 molecular subtype and its association with poor prognosis in 5-FU/LV, with lack of benefit from oxaliplatin and bevacizumab in NSABP C-08, but with benefit from irinotecan in CALGB C89803 trial	Soon Paik/ Yonsei University College of Medicine
CSC0108	<a href="#">NSABP C-08</a>	Examination of the tumor immune microenvironment (TME) to identify markers associated with prognosis and benefit from bevacizumab in NRG Oncology/NSABP C-08: Application of multispectral fluorescent-immunohistochemistry to improve prediction of clinical outcomes in colon cancer patients	Katherine Pogue-Geile/ NRG Oncology
CSC0111	<a href="#">RTOG 0522</a> <a href="#">RTOG-0129</a>	Quantitative histomorphometric based image risk classifier (QuHbIC) to predict risk of progression in p16+ OP-SCC patients to be validated on RTOG 0522 and RTOG 0129	James Lewis Jr./ Vanderbilt University
CSC0115	<a href="#">NSABP B-31</a>	Replication of genetic variants associated with cardiotoxicity in HER2+ breast cancer patients treated with chemotherapy and trastuzumab in NSABP-B31	Nadine Norton/ Mayo Clinic Florida
CSC0118	<a href="#">RTOG 9512</a>	Association of Oxidative Stress Pathway Alterations with Risk of Treatment Failure in RTOG9512: A Randomized Trial of Hyperfractionation Versus Conventional Fractionation in T2 Squamous Cell Carcinoma of the Vocal Cord	Quynh-Thu Le/ Stanford University
CSC0119	<a href="#">E1505</a>	Analysis of circulating tumor DNA for detection of minimal residual disease in resected stage IB-IIIa non-small cell lung cancer patients from ECOG-ACRIN E1505	Maximilian Diehn/ Stanford University

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0122	<a href="#">CALGB 89803</a>	Evaluation of individual methylated biomarkers as novel predictive epigenetic biomarkers in colon cancer cases from CALGB (Alliance) 89803	Stacey Cohen/ Fred Hutchinson Cancer Center
CSC0123	<a href="#">E2805</a>	Predictive plasmatic markers of progression of patients with non-metastatic clear cell renal cell carcinoma: their influence in the efficacy of anti-angiogenic drugs administered in an adjuvant setting	Gilles Pagès/ INSERM France
CSC0125	<a href="#">N0147</a>	Analysis of Plasma ctDNA in Stage III Colon Cancer Patients Treated with FOLFOX-based Adjuvant Chemotherapy (NCCTG N0147)	Frank Sinicrope/ Mayo Clinic MN
CSC0127	<a href="#">RTOG 0521</a>	Validation of a 22-Gene Genomic Classifier to Personalize Docetaxel Therapy in Men Receiving External Beam Radiotherapy and Androgen Suppression for Localized High Risk Prostate Cancer in RTOG-0521	Phuoc Tran/ Johns Hopkins University & Daniel Spratt/ University of Michigan & Felix Feng/ UCSF
CSC0129	<a href="#">CALGB 40601</a>	CPTAC Analysis of C40601	Matthew Ellis/ Baylor
CSC0133	<a href="#">S0226</a>	Effects of androgen receptor (AR) expression and activity on estrogen receptor alpha positive (ER+) breast cancer outcomes and immune cell composition in the SWOG S0226 study	Anthony Elias/ University of Colorado
CSC0134	<a href="#">NSABP B-28</a>	Tumor MicroEnvironment of Metastasis (TMEM) and Invasive Mena Isoforms: Validation as Prognostic and Predictive Markers in NSABP B28	Joseph Sparano/ Montefiore Medical Center/Albert Einstein College of Medicine
CSC0135	<a href="#">GOG-0240</a>	Angiogenic biomarker discovery to direct bevacizumab therapy in cervical cancer - Blood-based Angiome Profiling: An ancillary analysis of GOG-0240	Angeles Secord/ Duke Cancer Institute
CSC0139	<a href="#">NSABP B-42</a>	Prognostic and Predictive Performance of OncoMasTR multigene signature in NSABP B-42	John Crown/ St. Vincent's University Hospital, Dublin, Ireland

<b>Proposal #</b>	<b>Clinical trial(s) from which specimens were requested</b>	<b>Proposal Title</b>	<b>Proposal Principal Investigator/ Institution</b>
CSC0141	<a href="#">E2805</a>	Discovery and validation of novel genetic variants associated with outcome and safety of treatments of RCC patients in ASSURE (E2805)	Federico Innocenti/ University of North Carolina
CSC0143	<a href="#">RTOG-0617</a>	IDO Biomarker and Immunomodulating Cytokines to Predict Distant Metastasis and Survival after Chemoradiation in Non-Small Cell Lung Cancer: A Secondary Analysis for RTOG 0617 Study	Feng-Meng (Spring) Kong & Mitch Machtay/ Case Western Reserve University
CSC0145	<a href="#">N0147</a>	Evaluation of Consensus Molecular Subtypes as a Predictive Marker for Cetuximab Benefit in Stage III Colon Cancer (N0147)	Edmund (Scott) Kopetz/ MD Anderson Cancer Center
CSC0146	<a href="#">NSABP B-40</a>	Development and testing of RNA signatures predictive of pCR in NRG Oncology/NSABP clinical trial B-40	Katherine Pogue-Geile/ NSABP
CSC0147	<a href="#">CALGB 90601</a>	Associations of circulating tumor DNA with response to cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma enrolled onto CALGB (Alliance) 90601	Jonathan E. Rosenberg/ Memorial Sloan Kettering Cancer Center
CSC0148	<a href="#">GOG-0258</a>	Molecular Classification of Endometrial Advanced Stage Cancers and Association with Survival Outcomes: Ancillary Analysis of GOG-0258	Aine Clements/ Riverside Methodist Hospital, OH